Atypical developmental patterns of brain chemistry in children with autism spectrum disorder

JAMA Psychiatry

Volumn 70, Issue 9, 2013, Pages 964-974

  Corrigan, Neva M ^a   Shaw, Dennis W W ^a,d   Estes, Annette M ^b   Richards, Todd L ^a   Munson, Jeff ^a   Friedman, Seth D ^d   Dawson, Geraldine ^e,f   Artru, Alan A ^b   Dager, Stephen R ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c University of Washington   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e Autism Speaks Inc   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT;

AGE DISTRIBUTION; ARTICLE; AUTISM; BRAIN LEVEL; CHILD; CHILD DEVELOPMENT; DEVELOPMENTAL DISORDER; DISEASE COURSE; FEMALE; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PROTON NUCLEAR MAGNETIC RESONANCE; SCHOOL CHILD; WHITE MATTER;

EID: 84883549985     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.1388     Document Type: Article

References (53)

1. Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology. 2001;57(2):245-254. (Pubitemid 32667357)
2. Sparks BF, Friedman SD, Shaw DW, et al. Brain structural abnormalities in young children with autism spectrum disorder. Neurology. 2002;59(2):184-192. (Pubitemid 34779175)
3. Hazlett HC, Poe M, Gerig G, et al. Magnetic resonance imaging and head circumference study of brain size in autism: birth through age 2 years. Arch Gen Psychiatry. 2005;62(12):1366-1376. (Pubitemid 41746614)
4. Herbert MR, Ziegler DA, Makris N, et al. Localization of white matter volume increase in autism and developmental language disorder. Ann Neurol. 2004;55(4):530-540. (Pubitemid 38391970)
5. Chawarska K, Campbell D, Chen L, Shic F, Klin A, Chang J. Early generalized overgrowth in boys with autism. Arch Gen Psychiatry. 2011;68(10):1021-1031.
6. Ecker C, Suckling J, Deoni SC, et al; MRC AIMS Consortium. Brain anatomy and its relationship to behavior in adults with autism spectrum disorder: a multicenter magnetic resonance imaging study. Arch Gen Psychiatry. 2012;69(2):195-209.
7. Dager SR, Corrigan NM, Richards TL, Posse S. Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top Magn Reson Imaging. 2008;19(2):81-96.
8. Dager SR, Corrigan NM, Richards TW, Shaw D. Brain chemistry: magnetic resonance spectroscopy. In: Amaral D, Dawson G, Geshwind DH, eds. Autism Spectrum Disorder. Oxford, England: Oxford University Press; 2011:576-592.
9. Friedman SD, Shaw DW, Artru AA, et al. Regional brain chemical alterations in young children with autism spectrum disorder. Neurology. 2003;60(1):100-107. (Pubitemid 36070652)
10. Levitt JG, O'Neill J, Blanton RE, et al. Proton magnetic resonance spectroscopic imaging of the brain in childhood autism. Biol Psychiatry. 2003;54(12):1355-1366. (Pubitemid 37522159)
11. Friedman SD, Shaw DWW, Artru AA, Dawson G, Petropoulos H, Dager SR. Gray and white matter brain chemistry in young children with autism. Arch Gen Psychiatry. 2006;63(7):786-794.
12. DeVito TJ, Drost DJ, Neufeld RWJ, et al. Evidence for cortical dysfunction in autism: a protonmagnetic resonance spectroscopic imaging study. Biol Psychiatry. 2007;61(4):465-473. (Pubitemid 46185338)
13. Oner O, Devrimci-Ozguven H, Oktem F, Yagmurlu B, Baskak B, Munir KM. Proton MR spectroscopy: higher right anterior cingulate N-acetylaspartate/ choline ratio in Asperger syndrome compared with healthy controls. AJNR Am J Neuroradiol. 2007;28(8):1494-1498. (Pubitemid 47462934)
14. Hardan AY, Minshew NJ, Melhem NM, et al. An MRI and proton spectroscopy study of the thalamus in children with autism. Psychiatry Res. 2008;163(2):97-105.
15. Bernardi S, Anagnostou E, Shen J, et al. In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism. Brain Res. 2011;1380:198-205.
16. Aoki Y, Kasai K, Yamasue H. Age-related change in brain metabolite abnormalities in autism: a meta-analysis of proton magnetic resonance spectroscopy studies. Transl Psychiatry. 2012;2:e69.
17. Posse S, Dager SR, Richards TL, et al. In vivo measurement of regional brain metabolic response to hyperventilation using magnetic resonance: proton echo planar spectroscopic imaging (PEPSI). Magn Reson Med. 1997;37(6):858-865. (Pubitemid 27270762)
18. Corrigan NM, Shaw DWW, Richards TL, et al. Proton magnetic resonance spectroscopy and MRI reveal no evidence for brain mitochondrial dysfunction in children with autism spectrum disorder. J Autism Dev Disord. 2012;42(1):105-115.
19. Corrigan NM, Richards TL, Friedman SD, Petropoulos H, Dager SR. Improving 1H MRSI measurement of cerebral lactate for clinical applications. Psychiatry Res. 2010;182(1):40-47.
20. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659-685. (Pubitemid 24309810)
21. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30(3):205-223.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
23. Mullen E. Mullen Scales of Early Learning. Circle Pines, MN: American Guidance Services Inc; 1984.
24. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales. Circle Pines, MN: American Guidance Service Inc; 1984.
25. Guillemaud R. Uniformity correction with homomorphic filtering on region of interest. Proc IEEE ICIP. 1998;2:872-875. doi:10.1109/ICIP.1998.723695.
26. Petropoulos H, Friedman SD, Shaw DWW, Artru AA, Dawson G, Dager SR. Gray matter abnormalities in autism spectrum disorder revealed by T2 relaxation. Neurology. 2006;67(4):632-636. (Pubitemid 44273610)
27. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672-679. (Pubitemid 23360802)
28. Pinheiro J, Bates D, DeBroy S, Sarkar D; R Development Core Team. nlme: Linear and nonlinear mixed effects models. R package version 3.1-104. Wirtschaftsuniversität Wien: Vienna, Austria; 2012.
29. Gelman A, Hill J. Data Analysis Using Regression and Multilevel/ Hierarchical Models. Cambridge, England: Cambridge University Press; 2006.
30. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol. 2007;81(2):89-131. (Pubitemid 46282272)
31. Baslow MH. Functions of N-acetyl-L-aspartate and N-acetyl-L- aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem. 2000;75(2):453-459. (Pubitemid 30485425)
32. Coyle JT. The nagging question of the function of N- acetylaspartylglutamate. Neurobiol Dis. 1997;4(3-4):231-238. (Pubitemid 27465513)
33. Sampaio R, Truwit C. Myelination of the developing human brain. In: Nelson CA, Luciana M, eds. Handbook of Developmental and Cognitive Neuroscience. Cambridge, MA: MIT Press; 2001:35-44.
34. Hetherington HP, Pan JW, Spencer DD. 1H and spectroscopy and bioenergetics in the lateralization of seizures in temporal lobe epilepsy. J Magn Reson Imaging. 2002;16(4):477-483.
35. Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11(6):646-651. (Pubitemid 41685134)
36. Nakabayashi M, Suzaki S, Tomita H. Neural injury and recovery near cortical contusions: a clinical magnetic resonance spectroscopy study. J Neurosurg. 2007;106(3):370-377. (Pubitemid 46354288)
37. Dager SR, Friedman SD, Petropoulos H, Shaw DWW. Imaging evidence for pathological brain development in autism spectrum disorders. In: Zimmerman AW, ed. Autism: Current Theories and Evidence. New York, NY: Springer-Verlag; 2008:361-380.
38. Szatmari P, Paterson AD, Zwaigenbaum L, et al; Autism Genome Project Consortium. Mapping autism risk loci using genetic linkage and chromosomal rearrangements [published correction appears in Nat Genet. 2007;39(10): 1285].Nat Genet. 2007;39(3):319-328.
39. Durand CM, Betancur C, Boeckers TM, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007;39(1):25-27. (Pubitemid 46026497)
40. Billstedt E, Gillberg IC, Gillberg C. Autism after adolescence: population-based 13- to 22-year follow-up study of 120 individuals with autism diagnosed in childhood [published correction appears in J Autism Dev Disord. 2007;37(9):1822]. J Autism Dev Disord. 2005;35(3):351-360. (Pubitemid 41125973)
41. Howlin P, Goode S, Hutton J, Rutter M. Adult outcome for children with autism. J Child Psychol Psychiatry. 2004;45(2):212-229. (Pubitemid 38240270)
42. Shattuck PT, Seltzer MM, Greenberg JS, et al. Change in autism symptoms and maladaptive behaviors in adolescents and adults with an autism spectrum disorder. J Autism Dev Disord. 2007;37(9):1735-1747. (Pubitemid 47476598)
43. Dager SR, Corrigan NM, Estes A, Shaw DWW. Further commentary on mitochondrial dysfunction in autism spectrum disorder: assessment and treatment considerations. J Autism Dev Disord. 2012;42(4):643-646. doi:10.1007/s10803-011- 1352-4.
44. Dager SR, Friedman SD, Parow A, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004;61(5):450-458. (Pubitemid 38620843)
45. Beacher F, Simmons A, Daly E, et al. Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study. Arch Gen Psychiatry. 2005;62(12):1360-1365. (Pubitemid 41746613)
46. Berry GT, Wang ZJ, Dreha SF, Finucane BM, Zimmerman RA. In vivo brain myo-inositol levels in children with Down syndrome. J Pediatr. 1999;135(1):94-97. (Pubitemid 30180569)
47. Moore CM, Breeze JL, Kukes TJ, et al. Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry. 1999;45(9):1197-1202. (Pubitemid 29236561)
48. Wei C, Wang X, Chen M, Ouyang K, Song L-S, Cheng H. Calcium flickers steer cell migration. Nature. 2009;457(7231):901-905.
49. Mader I, Rauer S, Gall P, Klose U. (1)H MR spectroscopy of inflammation, infection and ischemia of the brain. Eur J Radiol. 2008;67(2):250-257.
50. Amundsen LB, Artru AA, Dager SR, et al. Propofol sedation for longitudinal pediatric neuroimaging research. J Neurosurg Anesthesiol. 2005;17(4):180-192. (Pubitemid 41395893)
51. Sakabe T, Nakakimura K. Effects of anesthetic agents and other drugs on cerebral blood flow, metabolism, and intracranial pressure. In: Cottrell JE, Smith DS, eds. Anesthesia and Neurosurgery. St Louis, MO: Mosby; 2001:129-143.
52. Zhu XH, Chen W. Observed BOLD effects on cerebral metabolite resonances in human visual cortex during visual stimulation: a functional (1)H MRS study at 4 T. Magn Reson Med. 2001;46(5):841-847. (Pubitemid 33019905)
53. Zhang H, Wang W, Gao W, et al. Effect of propofol on the levels of neurotransmitters in normal human brain: a magnetic resonance spectroscopy study. Neurosci Lett. 2009;467(3):247-251.